載入...
Phase II Study of Mocetinostat (MGCD0103) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma
BACKGROUND: The prognosis of patients with relapsed Hodgkin lymphoma, especially those who relapsed after stem cell transplant, remains poor, and the development of new agents for this relatively young patient population represents an unmet medical need. In this study, we examined the safety and eff...
Na minha lista:
| 發表在: | Lancet Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5042214/ https://ncbi.nlm.nih.gov/pubmed/22033282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70265-0 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|